Epidemiological data for hepatitis D in Africa

Authors’ reply

Jose Debes and Shemal Shah highlight the paucity of data from east Africa, one of our major findings. The authors draw attention to a study from Tanzania, where samples that initially tested positive for antibodies against hepatitis D virus by a commercial assay did not test positive on retesting with a second assay.¹ The performance of the second assay relative to the first was unknown. Given that the first assay was used widely in the studies included in our analysis without confirmation by a second assay, we elected not to take retesting into account for the study from Tanzania and to maintain consistency with data available from the other studies. Further research is required to determine whether there is a generalisable issue with the specificity of hepatitis D virus antibody testing in Africa. We agree that considerations of assay specificity are important in this setting, as also demonstrated.

Edouard Tuillon and colleagues describe the use of dried blood spots (DBSs) for the detection of antibodies against hepatitis D virus in a large survey of adult volunteers in Burkina Faso. Consistent with our conclusions,³ the authors observed localised clusters of endemicity, and exploration of the risk factors for hepatitis D virus infection in the same population would be of interest. The report indicates that DBS offer a promising tool for obtaining representative measurements of the prevalence of hepatitis D virus. Validation data will increase confidence in the reliability of DBS testing for antibodies against hepatitis D virus. Important technical challenges remain: use of elutes from DBS samples reduces overall testing sensitivity, and whether DBS testing is a suitable method for hepatitis D virus RNA detection in Africa remains to be demonstrated.

AMG reports consultancy and speaker fees from Abbott, AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and ViV. The University of Liverpool is the recipient of research funds from Bristol-Myers Squibb, Gilead, Janssen, and ViV for studies of which AMG is the principal investigator. AMG is employed as an expert scientist by Roche Pharma Research and Early Discovery (pRED). Roche pRED has no involvement in the work presented. All other authors declare no competing interests.

Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Alexander J Stockdale,
Apostolos Beloukas,
*Anna Maria Geretti

Institute of Infection and Global Health, University of Liverpool, Liverpool, UK (AJS, AB, AMJ); and Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi (AJS)